Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials

BMJ Open Gastroenterology

Volumn 3, Issue 1, 2016, Pages

  Yee, Brittany E ^a   Nguyen, Nghia H ^a   Jin, Minjuan ^b,c   Lutchman, Glen ^b   Lim, Joseph K ^d   Nguyen, Mindie H ^b  

^a UCSD MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c ZHEJIANG UNIVERSITY   (China)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

FIBROSIS; GENOTYPE; HEPATITIS C

Indexed keywords

RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; FATIGUE; FIBROSIS; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE;

EID: 84996731311     PISSN: None     EISSN: 20544774     Source Type: Journal    
DOI: 10.1136/bmjgast-2015-000056     Document Type: Article

References (37)

1. Childs-Kean LM, Hand EO. Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection. Clin Ther 2015; 37: 243-67.
2. Sadler MD, Lee SS. Revolution in hepatitis C antiviral therapy. Br Med Bull 2015; 113: 31-44.
3. Berenguer M, Schuppan D. Progression of liver fibrosis in post-Transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol 2013; 58: 1028-41.
4. Wang CS, Ko HH, Yoshida EM, et al. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586-99.
5. Shiffman ML, Esteban R. Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?. Liver Int 2012; 32(Suppl 1): 54-60.
6. Maasoumy B, Port K, Deterding K, et al. Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease. Eur J Gastroenterol Hepatol 2014; 26: 836-45.
7. Maasoumy B, Port K, Markova AA, et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS ONE 2013; 8: e55285.
8. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014; 146: 1176-92.
9. Pungpapong S, Aqel B, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015; 60(S4): 201A.
10. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-65.
11. AASLD/IDSA. Recommendations for testing, managing, and treating hepatitis C. (2015). http://www.hcvguidelines.org/full-report/retreatment-persons-whom-prior-Therapy-has-failed
12. EASL. Recommendations on Treatment of Hepatitis C. European Association for the Study of the Liver. (2014). http://files.easl.eu/easlrecommendations-on-Treatment-of-hepatitis-C.pdf
13. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. (2011). www.cochrane-handbook.org
14. Aqel BA, Pungpapong S, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology 2015; 62: 1004-12
15. Bichoupan K, Tandon N, Del Bello D, et al. Real world effectiveness and cost of simeprevir- And/or sofosbuvir-based HCV treatments: $175, 000 per SVR12. J Hepatol 2015; 62: S672.
16. Capraru CI, Kuczynski M, La D, et al. Efficacy and safety of sofosbuvir plus simeprevir in patients with advanced HCV cirrhosis. Hepatology 2014; 60(Suppl 1): 665A.
17. Czul F, Schiff E, Peyton A, et al. First ribavirin-free sofosbuvir and simeprevir treatment of hepatitis C genotype 1 patients with severe renal impairment (GFR 30 mL/min or dialysis. J Hepatol 2015 62: S670-1.
18. Dieterich D, Bacon BR, Flamm SL, et al. Evaluation of sofosbuvir and simeprevir-based regimens in the trio network: academic and community treatment of a real-world, heterogeneous population. Hepatology 2014; 60(Suppl 1): 220A.
19. Kwo P, Gitlin N, Nahass R, et al. A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment -naive and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1. J Hepatol 2015; 62: 1.
20. Lawitz E, Matusow G, DeJesus E, et al. A phase 3, open-label, single-Arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment -naive or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2. J Hepatol 2015; 62: 1.
21. Lin MV, Gogela NA, Wisocky JL, et al. Real world experience with sofosbuvir and simeprevir combination treatment in patients with HCV genotype 1. Hepatology 2014; 60(Suppl 1): 683A.
22. Lingala S, Satapathy SK, Dbouk N, et al. Safety and efficacy of simeprevir and sofosbuvir in patients with decompensated cirrhosis. Hepatology 2014; 60(Suppl 1): 688A.
23. Modi AA, Nazario H, Gonzalez SA, et al. Safety and efficacy of simeprevir + sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C induced cirrhosis. Hepatology 2014; 60(Suppl 1): 661A.
24. Pearlman BL, Ehleben C, Perrys M. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related child?s class A cirrhosis. Gastroenterology 2015; 148: 762-70.e2; quiz e11-2.
25. Roytman M, Ramikissoon R, Hong L, et al. Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the COSMOS regimen: including patients with advanced liver disease, and east Asian ancestry. J Hepatol 2015; 62: S671.
26. Saxena V, Nyberg L, Pauly M, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C infected patients with compensated and decompensated cirrhosis. Hepatology 2015; 62: 715-25.
27. Singh V, Frederick T, Holt EW, et al. Efficacy of simeprevir and sofosbuvir for treatment of cirrhotic patients with genotype 1 chronic hepatitis C- A single center experience. J Hepatol 2015; 62: 1.
28. Nainan OV, Alter MJ, Kruszon-Moran D, et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006; 131: 478-84.
29. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138: 447-62.
30. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
31. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93.
32. Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis [Internet]. ClinicalTrials.gov [Internet]. 2014 (cited 27 February 2015). https://clinicaltrials.gov/ct2/show/NCT02114151?term=simeprevir+AND+sofosbuvir&rank=6
33. Hospital VU. Real-life security and efficacy of DAA-based therapy in HCV/HIV-coinfected patients. Bethesda, MD: National Library of Medicine (US), 2014 [5 March 2015]. https://clinicaltrials.gov/ct2/show/NCT02057003?term=simeprevir&rank=19
34. An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant (GALAXY) [Internet]. ClinicalTrials.gov [Internet]. 2014 (cited 27 February 2015). https://clinicaltrials.gov/ct2/show/NCT02165189?term=simeprevir+AND +sofosbuvir&rank=1
35. Ireland JRD. Efficacy and safety study of simeprevir in combination with sofosbuvir in subjects with chronic genotype 4 hepatitis C virus infection. Bethesda, MD: National Library of Medicine (US), 2015 [5 March 2015]. https://clinicaltrials.gov/ct2/show/NCT02250807?. term=simeprevir&rank=9
36. NV JCI. An efficacy and safety study of a 8 or 12-week treatment regimen of simeprevir in combination with sofosbuvir in treatment-naive and experienced participants with chronic genotype 4 hepatitis C virus infection. Bethesda, MD: National Library of Medicine (US); 2014 [5 March 2015]. https://clinicaltrials.gov/ct2/show/NCT02278419?term=simeprevir&rank=12
37. Peter J, Ruane MD. Simeprevir in combination with sofosbuvir in treatment-naïve or -experienced adults with chronic genotype 4 hepatitis C virus infection. Bethesda, MD: National Library of Medicine (US), 2014 [5 March 2015]. https://clinicaltrials.gov/ct2/show/NCT02253550?term=simeprevir&rank=14